Perlegen Seeking Genes Responsible for Actos(R) and Avandia(R) Side-Effects; Completed Collection of 3,000 DNA Samples

    MOUNTAIN VIEW, CALIF., June 15 /CNW/ - Perlegen Sciences announced today
that it has completed the collection of more than 3,000 DNA samples from
diabetic patients treated with Actos(R) and Avandia(R) in order to analyze the
genetic variability associated with adverse events due to treatment with this
class of medications.

    An estimated 200 million people worldwide have type 2 diabetes, including
close to 20 million in the United States. In the late 1990s, insulin
sensitizing thiazolidinediones (TZDs, the class of drugs to which Actos(R) and
Avandia(R) belong) were approved in the United States for the treatment of
type 2 diabetes. The main side effect from TZDs is fluid retention, leading to
edema, weight gain, and potentially aggravating heart failure. Last week, the
US Food and Drug Administration requested "black box" labels be added to the
packaging of both drugs, warning about the risk of cardiovascular events. This
new labeling may significantly impact the use of these agents.

    Perlegen, a leader in identifying genetic variation related to drug
response and predisposition to disease, has collected DNA from more than 3,000
subjects in more than 160 centers worldwide who have been treated with
Actos(R) or Avandia(R). Perlegen will use these samples to identify genetic
variations that may contribute to a patient's risk of experiencing adverse
events. Results of these analyses may help to direct patients to the drug that
is most appropriate for their use, and may provide researchers with important
new targets or pathways for drug discovery and development. The company has
licensed its own phase III ready TZD from Mitsubishi Pharma.

    "Our early results have demonstrated a significant genetic component to
the adverse effect profile of these TZDs," commented David R. Cox, MD, PhD,
Perlegen's Chief Scientific Officer, "Through our analysis of this valuable
sample set, using both genotyping and sequencing technologies, we hope to
provide patients and physicians with critical decision making information,
while revealing biological insights that will enable the discovery of safer

    About Perlegen Sciences

    Perlegen's mission is to discover and commercialize genetic variations
that can make a difference to patients and physicians. The company's expertise
is in understanding human genetic variation within and across diverse patient
populations and in conducting studies aimed at identifying those variations
that are predictive of drug response. Perlegen also applies its expertise to
discovering genetic variations associated with disease, to enable the
discovery of novel targets leading to new therapeutics as well as clinically
useful diagnostics or biomarkers.

For further information:

For further information: Perlegen Sciences Rob Middlebrook, 650-625-4500
Chief Corporate Development Officer

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890